Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Povetacicept (ALPN-303), a Potent Dual BAFF/APRIL Antagonist in Development for the Treatment of Autoimmune Cytopenias, Suppresses Disease in a Mouse Model of Autoimmune Hemolytic Anemia

Katherine E. Lewis, Luana Griffin, Zahra Maria, Amanda Enstrom, Armand R. Bankhead, III, Stanford L. Peng, Stacey R. Dillon

Blood (2023) 142 (Supplement 1): 6462.

https://doi.org/10.1182/blood-2023-177786

Published: 2023

Journal Articles

A Randomized, Placebo-Controlled, Phase 1 Study in Healthy Adult Volunteers of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN303, a Potent Dual BAFF/APRIL Antagonist for the Treatment of Autoimmune Cytopenias

Stacey R. Dillon, Rupert Davies, Jason D. Lickliter, Kristi L. Manjarrez, Alina Smith, Mary C. Lessig, Lori Blanchfield, Russell J. Sanderson, Allison Chunyk, Tiffany Blair, Amanda Enstrom, Hany Zayed, Stanford L. Peng

Blood (2022) 140 (Supplement 1): 8401–8403.

https://doi.org/10.1182/blood-2022-155908

Published: 2022

Journal Articles

An Open Label Study of Alpn-101, a First-in-Class Dual CD28/ICOS Antagonist, in Subjects with Steroid-Resistant or Steroid-Refractory Acute Graft Versus Host Disease (aGVHD)

Jing Yang, PhD, Jan L. Hillson, MD, Kristi L. Manjarrez, Jennifer R. Wiley, DRSc, Gary D. Means, PhD, Stacey R. Dillon, PhD, Stanford L. Peng, MD,PhD

Blood (2019) 134 (Supplement_1): 372.

https://doi.org/10.1182/blood-2019-126034

Published: 2019

Journal Articles

"Switch" Transmembrane Immunomodulatory Proteins (TIPs) Consisting of High-Affinity PD-1 Extracellular Domains (PD-1 vIgDs) and Costimulatory Intracellular Domains Potently Enhance the Activity of TCR-Engineered T Cells

Steven D Levin, PhD, Hieu Nguyen, B.S., Joseph Kuijper, Rebecca P Wu, Ryan Swanson, B.S., Stanford L. Peng, MD, PhD

Blood (2018) 132 (Supplement 1): 2052.

https://doi.org/10.1182/blood-2018-99-117454

Published: 2018

Journal Articles

Therapeutic Candidate Alpn-101, a Dual ICOS/CD28 Antagonist, Potently Suppresses Human/NSG Mouse Xenograft Graft Vs. Host Disease (GvHD) in a Dose Ranging Study and Reduces Disease Activity in a Mouse Model of Hemophagocytic Lymphohistiocytosis (HLH)

Stacey R. Dillon, PhD, Katherine E. Lewis, PhD, Katherine Verbist, PhD, Paige Tedrick, PhD, Sabrin Albeituni, PhD, Ryan Swanson, B.S., Lawrence S. Evans, B.S., Steven D Levin, PhD, Mark W. Rixon, PhD, Stanford L. Peng, MD, PhD, Kim E. Nichols, MD, Kristine M. Swiderek, PhD

Blood (2018) 132 (Supplement 1): 2037.

https://doi.org/10.1182/blood-2018-99-110001

Published: 2018

Journal Articles

Novel Variant Ig Domain (vIgD) Proteins Generated Via Directed Evolution of Igsf Domains Have Therapeutic Efficacy in Animal Models of Graft Versus Host Disease

Steven D Levin, PhD, Lawrence S. Evans, Erika Rickel, Martin F. Wolfson, Stacey R. Dillon, PhD, Michael G. Kornacker, PhD, Ryan Swanson, Stanford L. Peng, MDPhD

Blood (2017) 130 (Supplement 1): 1892.

https://doi.org/10.1182/blood.V130.Suppl_1.1892.1892

Published: 2017

NARROW

Povetacicept (ALPN-303), a Potent Dual BAFF/APRIL Antagonist in Development for the Treatment of Autoimmune Cytopenias, Suppresses Disease in a Mouse Model of Autoimmune Hemolytic Anemia

A Randomized, Placebo-Controlled, Phase 1 Study in Healthy Adult Volunteers of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN303, a Potent Dual BAFF/APRIL Antagonist for the Treatment of Autoimmune Cytopenias

An Open Label Study of Alpn-101, a First-in-Class Dual CD28/ICOS Antagonist, in Subjects with Steroid-Resistant or Steroid-Refractory Acute Graft Versus Host Disease (aGVHD)

"Switch" Transmembrane Immunomodulatory Proteins (TIPs) Consisting of High-Affinity PD-1 Extracellular Domains (PD-1 vIgDs) and Costimulatory Intracellular Domains Potently Enhance the Activity of TCR-Engineered T Cells

Therapeutic Candidate Alpn-101, a Dual ICOS/CD28 Antagonist, Potently Suppresses Human/NSG Mouse Xenograft Graft Vs. Host Disease (GvHD) in a Dose Ranging Study and Reduces Disease Activity in a Mouse Model of Hemophagocytic Lymphohistiocytosis (HLH)

Novel Variant Ig Domain (vIgD) Proteins Generated Via Directed Evolution of Igsf Domains Have Therapeutic Efficacy in Animal Models of Graft Versus Host Disease

Email alerts

ASH Publications

American Society of Hematology

Povetacicept (ALPN-303), a Potent Dual BAFF/APRIL Antagonist in Development for the Treatment of Autoimmune Cytopenias, Suppresses Disease in a Mouse Model of Autoimmune Hemolytic Anemia

A Randomized, Placebo-Controlled, Phase 1 Study in Healthy Adult Volunteers of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN303, a Potent Dual BAFF/APRIL Antagonist for the Treatment of Autoimmune Cytopenias

An Open Label Study of Alpn-101, a First-in-Class Dual CD28/ICOS Antagonist, in Subjects with Steroid-Resistant or Steroid-Refractory Acute Graft Versus Host Disease (aGVHD)

"Switch" Transmembrane Immunomodulatory Proteins (TIPs) Consisting of High-Affinity PD-1 Extracellular Domains (PD-1 vIgDs) and Costimulatory Intracellular Domains Potently Enhance the Activity of TCR-Engineered T Cells

Therapeutic Candidate Alpn-101, a Dual ICOS/CD28 Antagonist, Potently Suppresses Human/NSG Mouse Xenograft Graft Vs. Host Disease (GvHD) in a Dose Ranging Study and Reduces Disease Activity in a Mouse Model of Hemophagocytic Lymphohistiocytosis (HLH)

Novel Variant Ig Domain (vIgD) Proteins Generated Via Directed Evolution of Igsf Domains Have Therapeutic Efficacy in Animal Models of Graft Versus Host Disease

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only